NENCINI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 3.032
EU - Europa 2.096
AS - Asia 1.453
SA - Sud America 156
Continente sconosciuto - Info sul continente non disponibili 39
AF - Africa 36
OC - Oceania 22
Totale 6.834
Nazione #
US - Stati Uniti d'America 2.967
RU - Federazione Russa 615
IT - Italia 489
SG - Singapore 448
PL - Polonia 443
CN - Cina 368
HK - Hong Kong 165
VN - Vietnam 134
BR - Brasile 121
IE - Irlanda 108
SE - Svezia 103
KR - Corea 96
FI - Finlandia 68
DE - Germania 65
FR - Francia 60
GB - Regno Unito 60
IN - India 57
BD - Bangladesh 51
CA - Canada 43
JO - Giordania 38
AU - Australia 22
JP - Giappone 20
ID - Indonesia 18
NL - Olanda 17
TR - Turchia 17
AR - Argentina 15
BE - Belgio 13
ES - Italia 11
UA - Ucraina 9
CH - Svizzera 8
NG - Nigeria 8
CI - Costa d'Avorio 7
CO - Colombia 7
MX - Messico 7
MA - Marocco 6
PK - Pakistan 6
CZ - Repubblica Ceca 5
GR - Grecia 5
IQ - Iraq 5
SA - Arabia Saudita 5
ZA - Sudafrica 5
EC - Ecuador 4
LT - Lituania 4
AT - Austria 3
KZ - Kazakistan 3
LV - Lettonia 3
PH - Filippine 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BJ - Benin 2
CL - Cile 2
CR - Costa Rica 2
DZ - Algeria 2
EE - Estonia 2
GE - Georgia 2
JM - Giamaica 2
MQ - Martinica 2
MY - Malesia 2
NI - Nicaragua 2
NP - Nepal 2
TN - Tunisia 2
UY - Uruguay 2
AM - Armenia 1
BB - Barbados 1
BH - Bahrain 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BY - Bielorussia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GD - Grenada 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KE - Kenya 1
MM - Myanmar 1
NO - Norvegia 1
OM - Oman 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TM - Turkmenistan 1
TW - Taiwan 1
Totale 6.796
Città #
Santa Clara 465
Warsaw 442
Ashburn 437
Singapore 314
San Jose 178
Fairfield 175
Hong Kong 139
Chandler 136
Dublin 109
Milan 106
Beijing 96
Seoul 96
Cambridge 84
Woodbridge 84
Ann Arbor 73
Houston 72
Seattle 70
Dallas 66
Wilmington 65
Council Bluffs 63
Hefei 57
Buffalo 48
Florence 48
The Dalles 46
New York 43
Ho Chi Minh City 42
Los Angeles 41
Munich 39
Lawrence 38
Altamura 35
Lauterbourg 34
Rome 34
Princeton 29
Hanoi 28
Moscow 25
Mumbai 23
Shanghai 23
Jacksonville 22
Helsinki 21
Phoenix 21
Chicago 20
Tokyo 20
Kent 19
Medford 19
Melbourne 19
Boardman 18
Figino 17
Paris 15
Turku 15
Boston 14
Toronto 14
London 13
Brussels 12
Jakarta 12
Lappeenranta 12
Frankfurt am Main 11
Palermo 11
São Paulo 10
Izmir 9
Luni 9
Norwalk 9
Abuja 8
Abidjan 7
Charlotte 7
Chennai 7
San Francisco 7
Washington 7
Atlanta 6
Bologna 6
Dong Ket 6
Redondo Beach 6
Andover 5
Bari 5
Bengaluru 5
Livorno 5
New Delhi 5
Orem 5
Ottawa 5
Padua 5
Queens 5
Turin 5
Amman 4
Amsterdam 4
Catania 4
Clifton 4
Falls Church 4
Genoa 4
Haiphong 4
Hải Dương 4
Ioannina 4
Johannesburg 4
Laurel 4
Montreal 4
Naples 4
Ninh Bình 4
Oklahoma City 4
Salerno 4
Salvador 4
Ankara 3
Baghdad 3
Totale 4.456
Nome #
A novel allergen-adjuvant conjugate suitable for specific immunotherapy of respiratory allergy 392
Treatment with 8-OH-modified adenine (TLR7 ligand)-allergen conjugates decreases T helper type 2-oriented murine airway inflammation 368
Dermatophagoides pteronyssinus group 2 allergen bound to 8-OH modified adenine reduces the Th2-mediated airway inflammation without inducing a Th17 response and autoimmunity 308
Efficacy and safety of mepolizumab (Anti-Interleukin-5) treatment in Gleich's syndrome 241
High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients 231
The TLR7 Ligand 9-Benzyl-2-Butoxy-8-Hydroxy Adenine Inhibits IL-17 Response by Eliciting IL-10 and IL-10-Inducing Cytokines. 213
Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. 208
The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment 208
Assays and strategies for immunogenicity assessment of biological agents. 204
Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab 196
A novel nDer p2-conjugated TLR7 down-modulates Th2-associated lung inflammation by using a therapeutical protocol 192
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. 187
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer 183
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. 175
Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis 172
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study 172
A modified adenine chemically coupled to allergen molecole redirects allergen-specific Th2 cells 169
Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience 164
Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. 164
A novel antigen-conjugated TLR7 ligand regulates the lung inflammation and Th2-mediated response in a murine model of asthma 163
Etanercept inhibits the TNF-α driven shifting of Th17 towards non-classic Th1 phenotype in juvenile idiopathic arthritis. 153
Post-translational modifications of fibrinogen: implications for clotting, fibrin structure and degradation 151
Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience 151
Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis 146
Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. 146
Hydroxy-adenines as in vivo and in vitro immunomodulators of allergic responses 144
Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. 142
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 141
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 139
Short and long-term effect of a novel nDer p2-conjugated TLR7 ligand in the prevention of allergic lung inflammation 136
Fibrinogen Structural Changes and Their Potential Role in Endometriosis-Related Thrombosis 135
Immunogenicity of Biological Agents: Basic Knowledge and Clinical Implications 122
Homocysteinylation of Fibrinogen: A Post-Translational Link to Thrombosis 115
Dietary Antioxidants and Natural Compounds in Preventing Thrombosis and Cardiovascular Disease 109
Modified (2-Butoxy-8-Hydroxy-9-Benzyl) adenine redirects type 2 murine lung inflammation by triggering TLR7 in dendritic cells 107
The Erythrocyte–ROS Axis in Thrombosis and Hemostasis 96
Fibrinogen Oxidation and Thrombosis: Shaping Structure and Function 90
Fibrinogen glycosylation and glycation: molecular insights into thrombosis and vascular disease 86
ROS‐induced modifications of fibrin clots connect immune responses to atherothrombosis in systemic lupus erythematosus 67
Complete blood count in neonatal Intensive care Unit (NICU): Performance comparison between POCT Sight OLO® and Sysmex XN-9100™ hematology analyzers 58
Reactive Nitrogen Species and Fibrinogen: Exploring the Effects of Nitration on Blood Clots 47
Reactive Oxygen Species–Induced Modifications of Fibrin Clots as a Link Between Immune Responses and Atherothrombosis in Systemic Lupus Erythematosus 29
null 14
Totale 6.834
Categoria #
all - tutte 19.960
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.960


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022180 0 0 16 5 8 11 7 19 7 11 45 51
2022/2023589 48 124 29 34 40 95 73 36 81 5 13 11
2023/2024291 15 23 32 24 34 38 21 58 6 11 10 19
2024/20251.624 64 169 102 262 416 181 40 82 92 56 81 79
2025/20262.464 252 269 227 183 265 95 303 119 158 154 146 293
2026/2027420 94 103 223 0 0 0 0 0 0 0 0 0
Totale 6.834